Home / Press Release / Global Irritable Bowel Syndrome with Constipation Drugs Market is Expected to Reach US$ 2.23 Bn by 2026

Global Irritable Bowel Syndrome with Constipation Drugs Market is Expected to Reach US$ 2.23 Bn by 2026

The latest market report published by Credence Research, Inc. “Irritable Bowel Syndrome with Constipation Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026” the irritable bowel syndrome with constipation drugs market was valued at US$ 1.30 Bn in 2017, and is expected to reach US$ 2.23 Bn by 2026, expanding at a CAGR of 6.2% from 2018 to 2026. 

Browse the full report Irritable Bowel Syndrome with Constipation Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-with-constipation-drugs-market

Market Insights

The global IBS-C drugs market is expected to progress at a CAGR of 6.2% during the forecast period from 2018 to 2026. North America is expected to be the largest regional market for IBS-C drugs followed by Europe and Asia Pacific. Gradual growth in physician and patient awareness corresponding to the perpetual growth in disease prevalence are the major growth contributors to the global IBS-C drugs market. 

The global IBS-C drugs market is expected to witness significant growth over the forecast period due to widespread adoption of IBS-C drugs. The recent FDA approvals and currently successful clinical trials of IBS drugs will further surge the market opportunities for IBS-C drugs during the forecast period. Pipeline products namely tenapanor, SYN-010 and relenopride are being developed for the treatment of IBS-C. The approval of these drugs would contribute to the further growth of the IBS-C drugs market. 

Growing geriatric population and rise in healthcare expenditure are further creating huge opportunities in the IBS-C drugs market. IBS-C is much prevalent in developed world, where dietary habits and work conditions contribute to higher risk of lifestyle-related gastrointestinal diseases. Majority of IBS-C drugs are widely accepted and the rise in FDA approvals to newer drugs are adding up to create further market opportunities. As a result, several market players are increasingly focusing on research and development activities to come with better and novel pharmaceutical solutions for treating IBS-C. 

North America predominates the IBS-C market owing to the rising prevalence of IBS-C patients, constant R&D activities, greater geriatric population, rise in adoption of unhealthy lifestyle and presence of manufacturers across this region. Plecanatide (Trulance) by Synergy Pharmaceuticals has been sent for NDA filling to the FDA (2017). Upon approval, it would contribute to the remunerative growth of IBS-C drugs market.

Market Competition Assessment:

Irritable bowel syndrome with constipation drugs market comprises a narrow competitive pool, thus creating opportunities for new emerging market players. Synergy Pharmaceuticals, Inc. has recently filed an NDA for its product Plecanatide (Trulance) for the treatment of IBS-C. Potential players contributing to this market are Abbott Laboratories, Inc., Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Fresenius Kabi AG, Ironwood Pharmaceuticals, Inc., Sanofi S.A., SK Biopharmaceuticals Co., Ltd., Sucampo AG and Synthetic Biologics, Inc.

Key Market Movements:

Contact Information
24/7 Research Support
Phone: +1-800-361-8290
sales@credenceresearch.com
Get in Touch with us
Join us on Facebook
Follow us on Twitter
Join us on LinkedIn
Add us on Google +